Daily Briefs

• AMAT Q124 revenues of $6.65 billion, in line with guidance and essentially flat both QoQ and YoY. Current quarter guidance also flat sequentially
• WFE valuations are at all time record highs while revenues remain on life support from China
• If China revenues fall off before non-China returns to growth, the WFE segment could be in for a world of pain.

• INOD is benefiting from the movement to incorporate artificial intelligence (“A.I.”) into many applications
• INOD provides the datasets required for training A.I. and it has quickly become a leading provider of such service
• The Company is now on pace to grow at a faster pace than expected and should lead to higher earnings and free cash flow in coming quarters

• Nvidia announced another sharp sales increase to $26 billion in quarterly revenues
• The company’s growth is far greater than hyperscaler CapEx growth, as standard servers yield to AI servers: Bad news for Intel & AMD
• Some of this may stem from an inventory build at the hyperscaler, which may lead to another Boom/Bust cycle similar to 2018 and 2022

• We are reiterating our Buy rating, $37 price target and projections after visiting Guess?
• stores in the New York City Metro area and Long Island.
• We believe the company continued to drive strong momentum in May, with Mother’s Day solid and the company’s focus on key fashion items, such as cargo pants, shorts, handbags, watches and active wear a plus.

• Recommendation to buy SPLS 10.75% Senior Unsecured Notes due Apr-27 in the 78c area
• Company is a B2B distributor of office supplies and professional categories in the US, with no retail stores
• Potential for 45% total return if refinanced at par one year before maturity, with current yield of 13.8%

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

• Glatfelter faced solvency issues after overpaying for Jacob Holm in late 2021
• Turnaround CEO Thomas Fahnemann appointed in July 2022 to address liquidity issues
• Reverse Morris Trust transaction with Berry Packaging leads to 60% increase in stock price, creating NewCo for potential successful turnaround.

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

• The in vitro testing examined the removal of EVs directly from plasma & was reviewed and examined by an independent 3rd party commercial lab & by NAMSA, AEMD’s CRO for its planned Australian oncology study.
• The data is a critical element enabling the company to move the Hemopurifier forward in clinical oncology studies towards potential regulatory approval and commercialization.
• The next step is for AEMD to add the data to its Clinical Investigator Brochure, which it will then submit to the Ethics Committees at clinical sites interested in participating in the planned trials in Australia and India.

• Tuya reported a strong 1Q24, with revenue of $61.7 million, up 30% Y/Y (consensus was for ~15% Y/Y growth).
• Gross margin continued to grow, up 360 bps Y/Y to 47.8% (a company record). IoT PaaS revenue grew 36% Y/Y to $45.6 million.
• Its 590-bp Y/Y margin improvement was significant to corporate margin growth. 

• Kinetic is a Permian midstream business formed from the merger of Altus Midstream and Blackstone’s Raptor I and Raptor II G&P businesses
• The company is the only large, pure-play Permian midstream business, with two business units focused on Midstream Logistics and Pipeline Transportation
• Kinetic, still 50% owned by Blackstone, is expected to generate reasonable profits in the foreseeable future and presents a stable investment option in the current market environment

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

• MIRA Pharmaceuticals is a preclinical-stage pharmaceutical company focused on the development and commercialization of new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia.
• The company announced it is in advanced discussions with a top cancer hospital to study Ketamir-2 for the treatment of cancer-related pain and depression.